A
Angharad N de Cates
Researcher at University of Oxford
Publications - 19
Citations - 295
Angharad N de Cates is an academic researcher from University of Oxford. The author has contributed to research in topics: Cognition & Agonist. The author has an hindex of 8, co-authored 17 publications receiving 208 citations. Previous affiliations of Angharad N de Cates include Coventry Health Care & Birmingham and Solihull Mental Health NHS Foundation Trust.
Papers
More filters
Reference EntryDOI
Fixed-dose combination therapy for the prevention of cardiovascular disease
Angharad N de Cates,Matthew R. B. Farr,Nicola Wright,Morag C. Jarvis,Karen Rees,Shah Ebrahim,Mark D. Huffman +6 more
TL;DR: To determine the effectiveness of fixed-dose combination therapy on reducing fatal and non-fatal CVD events and on improving blood pressure and lipid CVD risk factors for both primary and secondary prevention of CVD, nine randomised controlled trials were found.
Journal ArticleDOI
Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.
Ehete Bahiru,Angharad N de Cates,Matthew R. B. Farr,Morag C. Jarvis,Mohan Palla,Karen Rees,Shah Ebrahim,Mark D. Huffman +7 more
TL;DR: The low event rates for these outcomes and indirectness of evidence for comparing fixed-dose combination to usual care versus individual drugs suggest that these results should be viewed with caution.
Journal ArticleDOI
Mental well-being: an important outcome for mental health services?
TL;DR: Whether mental well-being has prognostic significance or other utility in this context is discussed, as well as how to measure it.
Journal ArticleDOI
Translating the promise of 5HT4 receptor agonists for the treatment of depression.
Susannah E. Murphy,Susannah E. Murphy,Angharad N de Cates,Angharad N de Cates,Amy Gillespie,Amy Gillespie,Beata R. Godlewska,Beata R. Godlewska,Jessica C. Scaife,Jessica C. Scaife,Lucy Wright,Lucy Wright,Philip J. Cowen,Philip J. Cowen,Catherine J. Harmer,Catherine J. Harmer +15 more
TL;DR: Evidence from animal studies that the 5-HT4 receptor is a promising target for the treatment of depression and cognitive disorders is reviewed, and a potential pathway for the efficient and cost-effective translation of these effects into humans and, ultimately, to the clinic is outlined.
Journal ArticleDOI
Choosing death in depression: a commentary on ‘Treatment-resistant major depressive disorder and assisted dying’
TL;DR: Commentary on Schuklenk and van de Vathorst's paper will focus on the premise of the argument around choosing death and some empirical clarification about competence in depression and the nature of treatment-resistant depression and its prognosis.